National Comprehensive Cancer Network

NCCN Research & Business Resources

Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions

Select a cancer below for additional information on active trials.

Adenoid Cystic Carcinoma

Alan L. Ho, MD, PhD

Memorial Sloan-Kettering Cancer Center

A Phase II Study of Axitinib (AG-013736) in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

 

Gastrointestinal Cancer

R. Kate Kelley, MD	UCSF Helen Diller Family Comprehensive Cancer Center	A Phase I/II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Halla Nimeiri, MD	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	A Phase I/II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Nikhil I. Khushalani, MD	Roswell Park Cancer Institute	Pralatrexate in Combination with Oxaliplatin in Advanced Esophago-Gastric Cancer: A Phase II Trial with Predictive Molecular Correlates

 

Gynecologic Cancer

Marcela G. del Carmen, MD, MPH

Massachusetts General Hospital Cancer Center

Phase I/II Study of Carboplatin and Pralatrexate in Patients with Recurrent Platinum Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

 

Head and Neck Cancers

Matthew Fury, MD, PhD	Memorial Sloan-Kettering Cancer Center	A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Matthew Fury, MD, PhD	Memorial Sloan-Kettering Cancer Center	Phase I Study of Induction Chemotherapy with Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Danielle Margalit, MD, MPH	Dana-Farber/Brigham and Women's Cancer Center	Phase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
Shanthi Marur, MD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase I/II Study of Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard Chemoradiation in HPV Negative Locally Advanced Stage III/IVa/IVb HNSCC Patients
Theodoros N. Teknos, MD	The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute	A Phase I Trial of Vorinostat in the Treatment of Advanced Oropharyngeal Carcinoma of the Head and Neck” Award
Ravindra Uppaluri, MD, PhD	Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine	A Phase II Window of Opportunity Trial with GSK1120212 in Surgically Resectable Oral Squamous Cell Cancer
Francis P. Worden, MD	University of Michigan Comprehensive Cancer Center	Phase II Trial Evaluating Axitinib in Patients with Unresetable, Recurrent or Metastatic Head and Neck Cancer

 

Hematologic Malignancies

Seema Bhat, MD	Roswell Park Cancer Institute	A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia
Jennifer Brown, MD, PhD	Dana-Farber Cancer Institute	Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL
Alessandra Ferrajoli, MD	The University of Texas MD Anderson Cancer Center	Phase II Study of Ofatumumab as front-line treatment in elderly, unfit patients with Chronic Lymphocytic Leukemia (CLL)
Francisco Hernandez, MD	Roswell Park Cancer Institute	Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma (MCL)
Michaela Liedtke, MD	Stanford Cancer Institute	A Phase I Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Shuo Ma, MD, PhD	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Correlative Studies in Conjunction with A Phase II Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

 

Lung Cancer

Jamie Chaft, MD	Memorial Sloan-Kettering Cancer Center	A Dose-Finding Study of Afatinib in Combination with Cisplatin or Carboplatin + Pemetrexed in Patients with EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Griffith Harsh, MD	Stanford Cancer Institute	Phase I Trial of Vorinostat Concurrent with Stereotactic Radiotherapy in Treatment of Brain Metastases from Non-Small Cell Lung Cancer
Ranee Mehra, MD	Fox Chase Cancer Center	Phase I Study of the HDAC Inhibitor Vorinostat with Chemotherapy and Radiation Therapy for the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Francisco Robert, MD	University of Alabama at Birmingham Comprehensive Cancer Center	Phase I/IIa Study of the Novel Combination of Bendamustine with Irinotecan Followed by Etoposide/ Carboplatin in Chemonaive Patients with Extensive Stage Small Cell Lung Cancer
Lecia Sequist, MD, MPH	Massachusetts General Hospital Cancer Center	Randomized Phase II Study Comparing Concise (3 months) versus Prolonged (2 years) Afatinib as Adjuvant Therapy for Patients with Resected Stage I-III NSCLC with EGFR Mutation

 

Melanoma

Paul Chapman, MD	Memorial Sloan-Kettering Cancer Center	Adjuvant Therapy of Stage IIIC BRAF-mutated Melanoma Patients with GSK2118436
Nikhil I. Khushalani, MD	Roswell Park Cancer Institute	Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma

 

Neuroendocrine/Carcinoid Tumors

Emily Bergsland, MD	UCSF Helen Diller Family Comprehensive Cancer Center	A Phase II Study of Axitinib in Advanced Carcinoid Tumors
Jonathan Strosberg, MD	Moffitt Cancer Center	A Phase II Study of Axitinib in Advanced Carcinoid Tumors
Halla Nimeiri, MD	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)

 

Sarcomas

Margaret von Mehren, MD	Fox Chase Cancer Center	Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma
William D. Tap, MD	Memorial Sloan-Kettering Cancer Center	A Phase IB/II Study of Gemcitabine and Docetaxel in Combination with Pazopanib (gem/doce/pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

 

Solid Tumors

Michaela Cristea, MD	City of Hope Comprehensive Cancer Center	Phase I Trial of Intraperitoneal nab-Paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
John Grecula, MD	The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute	Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients with 1-3 Brain Metastases from Solid Malignancies
Herbert I. Hurwitz, MD	Duke Cancer Institute	Phase I Dose Escalation of Pazopanib Plus TH302 in Advanced Solid Tumors
Manisha Shah, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	A Phase I Trial of GSK2118436 (BRAFi) and Pazopanib in Patients with BRAF-mutated Advanced Malignant Solid Tumors
Apostolia-Maria Tsimberidou, MD, PhD	The University of Texas MD Anderson Cancer Center	A Phase I Study of Bendamustine and Bevacizumab for Patients with Advanced Cancers
Jennifer J. Wheler, MD	The University of Texas MD Anderson Cancer Center	Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy

 

Thyroid Cancer

Nilofer S. Azad, MD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	A Phase I Study Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK 1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer
Laura QM Chow, MD	University of Washington/Seattle Cancer Care Alliance	A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
Manisha Shah, MD	The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute	A Randomized Phase 2 Study of Single Agent GSK2118436 (BRAFi) vs Combination Regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in Patients with BRAF Mutated Thyroid Carcinoma